Histological and molecular classification of breast cancer

what do we know?

Resumo

1. Lukong KE. Understanding breast cancer – The long and winding road. BBA Clin. 2017;7(1):64-77. http://dx.doi. org/10.1016/j.bbacli.2017.01.001 2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jernal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2018;68(6):394-424. https://doi. org/10.3322/caac.21492 3. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941-53. https://doi.org/10.1002/ijc.31937 4. Torre LA, Islami F, Siegel RL, Ward EM, Jemal A. Global cancer in women: Burden and trends. Cancer Epidemiol Biomarkers Prev. 2017;26(4):444-57. https://doi.org/10.1158/1055-9965.epi-16-0858 5. Brasil. Ministério da Saúde. Instituto Nacional de Câncer José Alencar Gomes da Silva. Estimativa 2020: Incidência de Câncer no Brasil. Brasil: INCA; 2019. 120 p. 6. Vuong D, Simpson PT, Green B, Cummings MC, Lakhani SR. Molecular classification of breast cancer. Virchows Arch. 2014;465(1):1-14. https://doi.org/10.1007/s00428-014-1593-7 7. Makki J. Diversity of breast carcinoma: Histological subtypes and clinical relevance. Clin Med Insights Pathol. 2015;8(1):23- 31. https://dx.doi.org/10.4137%2FCPath.S31563 8. Nounou MI, ElAmrawy F, Ahmed N, Abdelraouf K, Goda S, Syed-Sha-Qhattal H. Breast cancer: Conventional diagnosis and treatment modalities and recent patents and technologies. Breast Cancer Basic Clin Res. 2015;9(Suppl. 2):17-34. https:// dx.doi.org/10.4137%2FBCBCR.S29420 9. Henry NL, Cannon-Albright L. Breast Cancer Histologic Subtypes Show Excess Familial Clustering. Wiley Cancer. 2019;125(18):3131-8. https://doi.org/10.1002/cncr.32198 10. Masood S. Breast Cancer Subtypes: Morphologic and Biologic Characterization. Womens Health. 2016;12(1):103-19. https:// doi.org/10.2217%2Fwhe.15.99 REFERENCES 11. Akram M, Iqbal M, Daniyal M, Khan AU. Awareness and current knowledge of breast cancer. Biol Res. 2017;50(1):33. https://doi.org/10.1186/s40659-017-0140-9 12. Provenzano E, Ulaner GA, Chin SF. Molecular Classification of Breast Cancer. PET Clin. 2018;13(3):325-38. https://doi. org/10.1016/j.cpet.2018.02.004 13. Zangouri V, Akrami M, Tahmasebi S, Talei A, Hesarooeih AG. Medullary breast carcinoma and invasive ductal carcinoma: A review study. Iran J Med Sci. 2018;43(4):365-71. https://doi. org/10.21859/mci-supp-100 14. Sinn HP, Kreipe H. A brief overview of the WHO classification of breast tumors, 4th edition, focusing on issues and updates from the 3rd edition. Breast Care. 2013;8(2):149-54. https:// dx.doi.org/10.1159%2F000350774 15. Schwartz TL, Mogal H, Papageorgiou C, Veerapong J, Hsueh EC. Metaplastic breast cancer: Histologic characteristics, prognostic factors and systemic treatment strategies. Exp Hematol Oncol. 2013;2(1):31. https://dx.doi. org/10.1186%2F2162-3619-2-31 16. Vranic S, Schmitt F, Sapino A, Costa JL, Reddy S, Castro M, et al. Apocrine carcinoma of the breast: A comprehensive review. Histol Histopathol. 2013;28(11):1393-409. https://doi. org/10.14670/hh-28.1393 17. Vranic S, Feldman R, Gatalica Z. Apocrine carcinoma of the breast: A brief update on the molecular features and targetable biomarkers. Bosn J Basic Med Sci. 2017;17(1):9-11. https://doi. org/10.17305/bjbms.2016.1811 18. Marrazzo E, Frusone F, Milana F, Sagona A, Gatzemeier W, Barbieri E, et al. Mucinous breast cancer: A narrative review of the literature and a retrospective tertiary single-centre analysis. Breast. 2020;49(1):87-92. https://doi.org/10.1016/j. breast.2019.11.002 19. Dumitru A, Procop A, Iliesiu A, Tampa M, Mitrache L, Costache M, et al. Mucinous Breast Cancer: a Review Study of 5 Year Experience from a Hospital-Based Series of Cases. Maedica (Buchar). 2015;10(1):14-8. 7 Histological and molecular classification of breast cancer: what do we know Mastology 2020;30:e20200024 20. Cong Y, Qiao G, Zou H, Lin J, Wang X, Li X, et al. Invasive cribriform carcinoma of the breast: A report of nine cases and a review of the literature. Oncol Lett. 2015;9(4):1753-8. https:// dx.doi.org/10.3892%2Fol.2015.2972 21. Zhang WW, Wu SG, Ling YH, Sun JY, Long ZQ, Hua X, et al. Clinicopathologic characteristics and clinical outcomes of pure type and mixed type of tubular carcinoma of the breast: A singleinstitution cohort study. Cancer Manag Res. 2018;10(1):4509- 15. https://dx.doi.org/10.2147%2FCMAR.S177046 22. Fritz P, Bendrat K, Sonnenberg M, Trautmann C, Ott G, Heidemann E, et al. Tubular breast cancer. A retrospective study. Anticancer Res. 2014;34(7):3647-56. 23. Jurčić P, Kruslin B, Gatalica Z, Sanati S, Vranic S. Breast carcinoma with neuroendocrine features: a brief review. Endocr Oncol Metab. 2016;2(2):138-45. https://dx.doi. org/10.21040/eom/2016.2.2.6 24. Li Y, Du F, Zhu W, Xu B. Neuroendocrine carcinoma of the breast: A review of 126 cases in China. Chin J Cancer. 2017;36(1):45. https://dx.doi.org/10.1186%2Fs40880-017-0211-x 25. Thomas M, Kelly ED, Abraham J, Kruse M. Invasive lobular breast cancer: A review of pathogenesis, diagnosis, management, and future directions of early stage disease. Semin Oncol. 2019;46(2):121-32. https://doi.org/10.1053/j. seminoncol.2019.03.002 26. Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, Zhang L, et al. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis. 2018;5(2):77-106. https:// doi.org/10.1016/j.gendis.2018.05.001 27. Fragomeni SM, Sciallis A, Jeruss JS. Molecular Subtypes and Local-Regional Control of Breast Cancer. Surg Oncol Clin N Am. 2018;27(1):95-120. https://dx.doi.org/10.1016%2Fj.soc.2017.08.005 28. Burstein MD, Tsimelzon A, Poage GM, Covington KR, Fuqua SAW, Savage MI, et al. Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-negative Breast Cancer. Clin Cancer Res. 2015;21(7):1688-98. https://doi. org/10.1158/1078-0432.ccr-14-0432 29. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750-67. https:// dx.doi.org/10.1172%2FJCI45014 30. Lehmann BD, Jovanovic B, Chen X, Estrada M V, Johnson N, Shyr Y, et al. Refinement of Triple-Negative Breast Cancer Molecular Subtypes : Implications for Neoadjuvant Chemotherapy Selection. PLoS One. 2016;11(6):e0157368. https://doi.org/10.1371/journal.pone.0157368 31. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-52. https://doi.org/10.1038/35021093 32. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol. 2011;5(1):5-23. https://dx.doi. org/10.1016%2Fj.molonc.2010.11.003 33. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869-74. https://doi. org/10.1073/pnas.191367098 34. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci. 2003;100(14):8418-23. https://doi.org/10.1073/pnas.0932692100 35. Tsang JYS, Tse GM. Molecular Classification of Breast Cancer. Adv Anat Pathol. 2020;27(1):27-35. https://doi.org/10.1097/ pap.0000000000000232 36. Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, et al. Breast cancer. Nat Rev Dis Prim. 2019;5(1):66. https://doi.org/10.1038/s41572-019-0111-2 37. Parker JS, Mullins M, Cheung MCU, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160-7. https:// dx.doi.org/10.1200%2FJCO.2008.18.1370 38. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817- 26. https://doi.org/10.1056/nejmoa041588 39. Vijver MJV, He Y, Veer L, Dai H, Hart AAM, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347(25):1999-2009. https://doi. org/10.1056/nejmoa021967 40. Huang S, Murphy L, Xu W. Genes and functions from breast cancer signatures. BMC Cancer. 2018;18(1):473. https://doi. org/10.1186/s12885-018-4388-4 41. Vieira AF, Schmitt F. An update on breast cancer multigene prognostic tests-emergent clinical biomarkers. Front Med. 2018;5(1):248. https://dx.doi.org/10.3389%2Ffmed.2018.00248 42. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart- Gebhart M, Thürlimann B, et al. Personalizing the treatment of women with early breast cancer: Highlights of the st gallen international expert consensus on the primary therapy of early breast Cancer 2013. Ann Oncol. 2013;24(9):2206-23. https:// dx.doi.org/10.1093%2Fannonc%2Fmdt303 43. Gao JJ, Swain SM. Luminal A Breast Cancer and Molecular Assays: A Review. Oncologist. 2018;23(5):556-65. https:// dx.doi.org/10.1634%2Ftheoncologist.2017-0535 44. Hashmi AA, Aijaz S, Khan SM, Mahboob R, Irfan M, Zafar NI, et al. Prognostic parameters of luminal A and luminal B intrinsic breast cancer subtypes of Pakistani patients. World J Surg Oncol. 2018;16(1):1-6. https://doi.org/10.1186/s12957-017-1299-9 45. Rocca A, Farolfi A, Maltoni R, Carretta E, Melegari E, Ferrario C, et al. Efficacy of endocrine therapy in relation to progesterone receptor and Ki67 expression in advanced breast cancer. Breast Cancer Res Treat. 2015;152(1):57-65. https://doi. org/10.1007/s10549-015-3423-2 46. Cheang MCU, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101(10):736- 50. https://dx.doi.org/10.1093%2Fjnci%2Fdjp082 47. Tsoutsou PG, Vozenin MC, Durham AD, Bourhis J. How could breast cancer molecular features contribute to locoregional treatment decision making? Crit Rev Oncol Hematol. 2017;110(1):43-8. http://dx.doi.org/10.1016/j.critrevonc.2016.12.006